Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by XBiotech Inc. XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer June 18, 2024 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus January 04, 2024 From XBiotech Inc. Via GlobeNewswire Tickers XBIT Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis November 14, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke September 26, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer August 30, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial August 08, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients May 22, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares May 17, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke April 17, 2023 From XBiotech Inc. Via GlobeNewswire Tickers XBIT XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer October 13, 2022 From XBiotech Inc. Via GlobeNewswire Tickers XBIT Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.